Treating Pulmonary Embolism with Laguna Thrombectomy System (TRUST)

Description

This is a prospective, multi-center, pivotal study to demonstrate the safety and effectiveness of the Laguna Thrombectomy System for the treatment of pulmonary embolism. The Laguna Thrombectomy System is an investigational device which consists of the Laguna Clot Retriever™ System and the Malibu Aspiration Catheter™ System. These devices are manufactured by Innova Vascular, Inc.

Conditions

Pulmonary Embolism

Study Overview

Study Details

Study overview

This is a prospective, multi-center, pivotal study to demonstrate the safety and effectiveness of the Laguna Thrombectomy System for the treatment of pulmonary embolism. The Laguna Thrombectomy System is an investigational device which consists of the Laguna Clot Retriever™ System and the Malibu Aspiration Catheter™ System. These devices are manufactured by Innova Vascular, Inc.

Treating Pulmonary Embolism with Laguna Thrombectomy System (TRUST)

Treating Pulmonary Embolism with Laguna Thrombectomy System (TRUST)

Condition
Pulmonary Embolism
Intervention / Treatment

-

Contacts and Locations

Irvine

University of California Irvine, Irvine, California, United States, 92697

Long Beach

Memorial Care Long Beach Medical Center, Long Beach, California, United States, 90806

Mission Viejo

Mission Hospital Regional Medical Center, Mission Viejo, California, United States, 92691

Orange

St. Joseph Hospital of Orange, Orange, California, United States, 92868

Washington

George Washington University, Washington, District of Columbia, United States, 20037

Bradenton

Manatee Memorial Hospital, Bradenton, Florida, United States, 34209

Tampa

AdventHealth Tampa, Tampa, Florida, United States, 33613

Chicago

Rush University Medical Center, Chicago, Illinois, United States, 60612

Albany

Albany Medical Center, Albany, New York, United States, 12210

Chapel Hill

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States, 27599

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. ≥ 18 years of age; \< 85 years old
  • 2. RV/LV ratio \> 0.9 as determined by CTA
  • 3. Systolic blood pressure \> 90 mmHg
  • 4. Heart rate ≤ 120
  • 5. Patient is deemed eligible for procedure by the interventional investigator
  • 6. CTA evidence of proximal PE (filling defect in at least one main or lobar pulmonary artery)
  • 7. PE Symptom duration ≤ 14 days
  • 1. Systolic pulmonary artery pressure \> 70 mmHg on initial invasive hemodynamic assessments
  • 2. Life expectancy of \< 90 days in the opinion of investigator at the time of enrollment
  • 3. Subject pregnant or breast feeding
  • 4. Current participation in another drug or medical device treatment study
  • 5. In active chemotherapy or radiation treatment for a malignancy during the course of the study
  • 6. Any intravascular administration of a fibrinolytic agent (such as Alteplase or Tenecteplase) within the last 30 days
  • 7. Presence of recently placed (\<8 weeks) intracardiac devices (such as pacemaker leads) in the right ventricle or right atrium
  • 8. History of prior PE within the past 90 days
  • 9. FiO2 Requirement: \> 40% (6 LPM) to keep oxygen saturation \> 90%
  • 10. Hematocrit: \< 28%
  • 11. Platelets: \< 100,000/microliter
  • 12. Serum Creatinine: \> 2 mg/dL
  • 13. International Normalized Ratio (INR): \> 3
  • 14. Major Trauma Injury Severity Score (ISS): \> 15
  • 15. Cardiovascular or pulmonary surgery within the last 7 days
  • 16. Known bleeding diathesis or coagulation disorder that cannot be managed with anti-coagulation
  • 17. History of known severe or chronic pulmonary arterial hypertension
  • 18. History or chronic left heart disease with left ventricular ejection fraction \< 30%
  • 19. History of underlying lung disease that is oxygen dependent
  • 20. History of chest irradiation
  • 21. Known anaphylactic reaction to radiographic contrast agents that cannot be pretreated
  • 22. Any absolute contraindication to systemic or therapeutic dosage of heparin or anticoagulants
  • 23. Imaging or other evidence that suggests, in the opinion of the investigator, the subject is not appropriate for mechanical thrombectomy intervention (e.g., inability to navigate to target location, predominantly chronic clot or non-clot embolus)
  • 24. Known presence of clot in transit within right atrium or ventricle

Ages Eligible for Study

18 Years to 85 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Innova Vascular, Inc.,

Study Record Dates

2025-10